Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

Summary

The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer (mCRC) after failure of at least 2 lines of standard treatment

Timeline

Start

2016-07-05

Primary completion

2016-09-09

Completion

2016-09-09

Outcome

Outcome not reported

Stopped: “Substance discontinued”

Drugs

Indications